Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650713 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 228
- Enrollment target
NCT02650713: Completed Phase 1 study, sponsored by Hoffmann-La Roche.
NCT02650713 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 228 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (280% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650713, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 228 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, dose-escalation and expansion Phase Ib clinical study of RO6958688 in combination with atezolizumab. Part I of the study is subdivided into parts IA and IB. Part IA is dose escalation with a starting dose of 5 mg of RO6958688 given QW (once a week) and a fixed, flat dose of 1200 mg given Q3W (every 3 weeks) of atezolizumab, to evaluate the safety and determine the MTD of RO6958688 in combination with atezolizumab. Part IB is a dose/schedule finding part that will explore different administration schedules of RO6958688 in combination with atezolizumab (1200 mg Q3W) to establish the appropriate dose/schedule of RO6958688 in combination with atezolizumab.
Interventions
- DRUG Atezolizumab
- DRUG RO6958688
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2016-01-07 |
| Est. Completion | 2020-01-13 |
| Phase | Phase 1 |
What the finished NCT02650713 record still lists
NCT02650713 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (280% higher).
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02650713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02650713 about?
NCT02650713 is a clinical study titled "A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors". This is an open-label, multicenter, dose-escalation and expansion Phase Ib clinical study of RO6958688 in combination with atezolizumab. Part I of the study is subdivided into parts IA and IB. Part IA is dose escalation with a starting dose of 5 mg of RO6958688 given QW (once a week) and a fixed, fl...
What is the current status of trial NCT02650713?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 228 participants. The study started on 2016-01-07. Estimated completion is 2020-01-13.
What interventions are being tested in trial NCT02650713?
The interventions under investigation include: Atezolizumab (DRUG), RO6958688 (DRUG).
Who is sponsoring clinical trial NCT02650713?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02650713's enrollment target sits among peer trials
228 221st of 2000 higher than 1,780 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI